Apellis Pharmaceuticals, Inc. to Post FY2025 Earnings of $2.23 Per Share, Wedbush Forecasts (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Stock analysts at Wedbush lowered their FY2025 earnings estimates for shares of Apellis Pharmaceuticals in a report issued on Wednesday, April 17th. Wedbush analyst L. Chico now anticipates that the company will post earnings of $2.23 per share for the year, down from their previous forecast of $2.24. Wedbush currently has a "Neutral" rating and a $57.00 target price on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.33) per share.

A number of other analysts have also commented on the stock. The Goldman Sachs Group boosted their price target on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a "buy" rating in a research note on Tuesday, January 9th. Jefferies Financial Group upgraded shares of Apellis Pharmaceuticals from a "hold" rating to a "buy" rating and boosted their price target for the company from $68.00 to $80.00 in a research note on Monday, February 5th. Robert W. Baird restated an "outperform" rating and set a $81.00 price target on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. JPMorgan Chase & Co. upped their target price on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 6th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $85.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday, April 9th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $77.93.

Apellis Pharmaceuticals Price Performance

APLS stock traded down $0.52 during midday trading on Thursday, reaching $47.51. 1,835,768 shares of the company's stock traded hands, compared to its average volume of 1,503,547. The firm's fifty day moving average price is $60.54 and its 200-day moving average price is $57.04. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10. Apellis Pharmaceuticals has a 52 week low of $19.83 and a 52 week high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, meeting the consensus estimate of ($0.73). The company had revenue of $146.38 million during the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. Apellis Pharmaceuticals's revenue for the quarter was up 545.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.50) EPS.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Future Financial Wealth Managment LLC purchased a new stake in Apellis Pharmaceuticals during the first quarter valued at about $29,000. First Horizon Advisors Inc. lifted its holdings in Apellis Pharmaceuticals by 69.0% during the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company's stock valued at $25,000 after purchasing an additional 265 shares during the last quarter. Covestor Ltd lifted its holdings in Apellis Pharmaceuticals by 564.2% during the third quarter. Covestor Ltd now owns 797 shares of the company's stock valued at $30,000 after purchasing an additional 677 shares during the last quarter. Stephens Consulting LLC purchased a new stake in Apellis Pharmaceuticals during the third quarter valued at about $38,000. Finally, US Bancorp DE lifted its holdings in shares of Apellis Pharmaceuticals by 391.2% in the first quarter. US Bancorp DE now owns 1,110 shares of the company's stock worth $56,000 after buying an additional 884 shares in the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Adam J. Townsend sold 3,413 shares of the business's stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $65.00, for a total value of $221,845.00. Following the transaction, the insider now directly owns 94,507 shares of the company's stock, valued at approximately $6,142,955. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 250,000 shares of the company's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $64.11, for a total transaction of $16,027,500.00. Following the sale, the chief executive officer now directly owns 313,662 shares of the company's stock, valued at $20,108,870.82. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Adam J. Townsend sold 3,413 shares of the company's stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $65.00, for a total transaction of $221,845.00. Following the sale, the insider now directly owns 94,507 shares in the company, valued at $6,142,955. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 406,651 shares of company stock valued at $25,130,257. 7.50% of the stock is owned by insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).